Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Shire says AbbVie should not renege on merger deal
Yahoo/Reuters
Wednesday, October 15, 2014 - 8:07am
tags:
Shire, AbbVie, M&A, tax inversions
Medgenics posts third-quarter loss of $3 million
Yahoo/AP
Wednesday, October 15, 2014 - 8:04am
tags:
Medgenics, earnings
Will an FDA Policy Shift on Fixed-Dose Drug Approvals Anger Pharma?
WSJ Pharmalot
Tuesday, October 14, 2014 - 9:26pm
tags:
drug approvals, FDA
A Quick Look at Pfizer Inc.'s Drug Development Pipeline
Motley Fool
Tuesday, October 14, 2014 - 9:24pm
tags:
Pfizer
Astellas dives into gene therapy with a Harvard expert in tow
Fierce Biotech
Tuesday, October 14, 2014 - 9:23pm
tags:
Astellas, gene therapy, Retinitis pigmentosa
AbbVie Board to Reconsider Recommendation for Shire Deal
Bloomberg
Tuesday, October 14, 2014 - 9:19pm
tags:
AbbVie, Shire, M&A
J&J hikes 2014 forecast for a third time
Yahoo/AP
Tuesday, October 14, 2014 - 1:08pm
tags:
JNJ
Medtronic Begins Study of First Predictive Low Glucose Management Technology-Critical Step in Development of Artificial Pancreas
Yahoo
Tuesday, October 14, 2014 - 11:32am
tags:
Medtronic, devices, artificial pancreas
Concert Pharmaceuticals' Spasticity Drug Gets Positive Reviews
Drug Discovery and Development
Tuesday, October 14, 2014 - 11:25am
tags:
Concert Pharmaceuticals, spasticity, CTP-354
Gilead Sciences Falls Amid Worries Over Hep-C Drug Price
TheStreet.com
Tuesday, October 14, 2014 - 11:22am
tags:
Gilead Sciences, hepatitis C, drug pricing, Harvoni
Management Incentives Could Be Bonus For AstraZeneca
WSJ Online
Tuesday, October 14, 2014 - 11:16am
tags:
AstraZeneca, executive pay
GW Pharma's cannabis-based drug comes up short in ulcerative colitis
Fierce Biotech
Tuesday, October 14, 2014 - 10:15am
tags:
GW Pharma, ulcerative colitis, GWP42003
Retrophin sells non-core assets
Seeking Alpha
Tuesday, October 14, 2014 - 10:13am
tags:
Retrophin
The top 10 most expensive drugs of 2013
Fierce Pharma
Tuesday, October 14, 2014 - 10:05am
tags:
drug pricing, Soliris, Alexion, Naglazyme, Biomarin, Kalydeco, Vertex, Cinryze, Shire, Sprycel, Bristol-Myers Squibb, Pomalyst, Celgene, Xyrem, Jazz Pharmaceuticals, Erbitux, Merck KGaA, Revlimid, Questcor, Mallinckrodt, H.P. Acthar Gel
If AbbVie Discounts its Hep C Drug, Would Pricing Reach a Tipping Point?
WSJ Pharmalot
Tuesday, October 14, 2014 - 9:51am
tags:
AbbVie, drug pricing, hepatitis C, Gilead Sciences
FDA staff wants Pfizer to keep black box warning on anti-smoking drug
Yahoo/Reuters
Tuesday, October 14, 2014 - 9:49am
tags:
FDA, Pfizer, black box, Chantix, smoking cessation
AstraZeneca looks to EU decision for next cancer drug boost
Yahoo/Reuters
Tuesday, October 14, 2014 - 9:48am
tags:
AstraZeneca, Europe, olaparib, ovarian cancer
The Gilead Effect
The Morning Consult
Tuesday, October 14, 2014 - 8:38am
tags:
Gilead Sciences, drug pricing, Sovaldi
NewLink Starts Human Trials For Ebola Vaccine; Stock Soars 23%
Bidness Etc.
Tuesday, October 14, 2014 - 8:29am
tags:
NewLink Genetics, ebola virus, vaccines, VSV-EBOV
Novartis joins an Atlas syndicate to back cancer drug upstart Raze
Fierce Biotech
Tuesday, October 14, 2014 - 8:25am
tags:
Novartis, cancer, Raze, Atlas Venture

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Cleaning Up the Medical Literature
In the Pipeline
Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.